Common blood pressure medicine blocks molecule that can trigger the disease
A drug commonly used to control high blood pressure may also help prevent the onset of Type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz Medical Campus and the University of Florida (UF) in Gainesville.
The study was published online this week in the Journal of Clinical Investigation.
“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, MD, a researcher at the Barbara Davis Center for Childhood Diabetes and associate professor of medicine at CU Anschutz. “We made this discovery using a supercomputer, on the lab bench, in mice and in humans.”
The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children. It is on the World Health Organization’s list of essential drugs.
But like many drugs used for one condition, Michels and his colleagues found it useful for something totally unrelated.
Some 60 percent of people at risk of getting Type 1 diabetes possess the DQ8 molecule which significantly increases the chance of getting the disease. The researchers believed that if they could block specifically the DQ8 molecule they could also block the onset of the disease.
“All drugs have off-target effects. If you take too much acetaminophen you can hurt your liver,” Michels said. “We took every FDA-approved small molecule drug and analyzed HLA-DQ8 binding through a supercomputer. We searched a thousand orientations for each drug to identify those that would fit within the DQ8 molecule binding groove.”
After running thousands of drugs through the supercomputer, they found that methyldopa not only blocked DQ8, but it didn’t harm the immune function of other cells like many immunosuppressant drugs do.
The research spanned 10 years and its efficacy was shown in mice and in 20 Type 1 diabetes patients who took part in a clinical trial at the Barbara Davis Center at the University of Colorado School of Medicine.
“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes,” Michels said. “The goal with this drug is to delay or prevent the onset of the disease among those at risk.”
The drug is taken orally, three times a day.
Implications for treatment
Michels and UF Health researcher David Ostrov, PhD, hope this same approach of blocking specific molecules can be used in other diseases.
“This study has significant implications for treatment of diabetes and also other autoimmune diseases,” said Ostrov, associate professor of pathology, immunology and laboratory medicine in the UF College of Medicine and a member of the UF Health Cancer Center, Genetics Institute and Center for NeuroGenetics. “This study suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others.”
The next step will be a larger clinical trial sponsored by the National Institutes of Health in spring.
“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at risk for the disease,” Michels said. “This is very significant development.”
The Latest on: Type 1 diabetes
- Local diabetes center encouraging kids with Type 1 to apply for trip to DC on October 6, 2018 at 7:40 am
IDAHO FALLS — A local diabetes center is standing behind a national nonprofit organization in its efforts to find young applicants for a trip to meet members of Congress. Kids ages 4 to 17 with Type 1 ... […]
- Blood sugar control tied to long-term brain health with type 1 diabetes on October 5, 2018 at 2:51 pm
(Reuters Health) - People with type 1 diabetes who are able to maintain good blood sugar control may reduce their long-term risk of developing dementia, a U.S. study suggests. Among more than 3,400 ty... […]
- Lilly's Novel Diabetes Candidate Shows Promise in Phase II on October 5, 2018 at 8:58 am
The company said that GIP/GLP-1 RA will be studied in a large phase III program to be called SURPASS. Phase III studies for type II diabetes are expected to begin early next year and be completed ... […]
- Positive Results for Empagliflozin in Type 1 Diabetes Trials on October 5, 2018 at 8:02 am
Results from the Phase 3 EASE program showed that treatment with empagliflozin, as an adjunct to insulin in patients with type 1 diabetes, led to improved glycemic control without increasing hypoglyce... […]
- Lexicon Likely Looking At Even More Competition In Type 1 Diabetes on October 5, 2018 at 7:27 am
Data from Phase III trials of Lilly/Boehringer's Jardiance in Type 1 diabetes supports submission and commercialization, bringing another competitor into the market. Lexicon's sotagliflozin is not ... […]
- Cases of type 1 diabetes diagnosed after the age of 30 are frequently not identified and may be misdiagnosed as type 2 diabetes on October 5, 2018 at 3:13 am
New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) reveals that many cases of type 1 diabetes (T1D) diagnosed after the age of 30 are ... […]
- Twincretin, a Dual GIP/GLP-1 Agonist, Excites in Type 2 Diabetes on October 4, 2018 at 10:44 am
BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," sho... […]
- Discovery opens door to new therapies for type 1 diabetes on October 4, 2018 at 2:45 am
Researchers at St Vincent’s Institute in Melbourne have identified a key target of the immune response that causes type 1 diabetes. Type 1 diabetes is an incurable autoimmune disease caused by the des... […]
- JDRF One Walk Houston type 1 diabetes fundraiser set for Nov. 3 on October 3, 2018 at 10:15 pm
Team Carson's Caped Crusader are all smiles during a previous year's One Walk Houston event. Team Carson's Caped Crusader are all smiles during a previous year's One Walk Houston event. The crowd duri... […]
- Millburn and Mendham High School Football Programs Team Up To Tackle Type 1 Diabetes on October 3, 2018 at 8:34 pm
MILLBURN, NJ - The Millburn High School football program is teaming up with the Mendham High School football program to raise funds for the Juvenile Diabetes Research Foundation (JDRF). The varsity fo... […]
via Google News and Bing News